Reported Q: Q3 2025 Rev YoY: -20.2% EPS YoY: -474.7% Move: -5.67%
Precision Optics
POCI
$5.32 -5.67%
Exchange NASDAQ Sector Healthcare Industry Medical Instruments Supplies
Q3 2025
Published: May 15, 2025

Company Status Snapshot

Fast view of the latest quarter outcome for POCI

Reported

Report Date

May 15, 2025

Quarter Q3 2025

Revenue

4.19M

YoY: -20.2%

EPS

-0.30

YoY: -474.7%

Market Move

-5.67%

Previous quarter: Q2 2025

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

  • Revenue of $4.19M down 20.2% year-over-year
  • EPS of $-0.30 decreased by 474.7% from previous year
  • Gross margin of 10.0%
  • Net income of -2.10M
  • "We have corrected the root cause of these issues and are on a pathway to optimal production operations." - Joe Forkey
POCI
Company POCI

Executive Summary

Precision Optics reported QQ3 2025 revenue of $4.20 million, down 20.2% year-over-year and 7.5% quarter-over-quarter, with a gross margin of 10.0% (vs. 35.0% in the year-ago quarter). The quarterly results were heavily affected by production yield challenges on the single-use cystoscope program, which led to a line shutdown and increased non-billable sustaining engineering, contributing to an EBITDA shortfall and a net loss of $2.10 million for the quarter. Management communicated that the root causes have been identified and corrected, and the company remains focused on ramping production and monetizing a robust aerospace and single-use endoscope backlog. A key near-term catalyst is the Unity platform rollout, which Cisco-like modular design is intended to shorten time to market and expand the addressable endoscope market, supported by a backlog that management cites as “greater than $6 million” and a minimum annual aerospace commitment of about $4 million for 2025–2026.

Management signaled confidence in a Q4 inflection point, guiding to approximately $6 million in revenue next quarter as production scales and the Unity-driven pipeline converts to billable revenue. The balance sheet shows liquidity support from a roughly $5 million equity raise in the quarter, ending cash of about $2.55 million, and a net cash position after financing activity of roughly $1.88 million in net debt (net cash figure negative). While near-term profitability remains a work in progress, the company has a clear operational plan: resolve yield issues, expand aerospace output (including a second cystoscope line in H1 FY2026), and accelerate Unity adoption across potential customers. This sets up a multi-quarter path toward revenue growth and potential EBITDA positivity if production efficiency and demand momentum persist.

Key Performance Indicators

Revenue
Decreasing
4.19M
QoQ: -7.53% | YoY: -20.15%
Gross Profit
Decreasing
417.98K
9.99% margin
QoQ: -60.93% | YoY: -77.51%
Operating Income
Decreasing
-2.04M
QoQ: -123.98% | YoY: -688.42%
Net Income
Decreasing
-2.10M
QoQ: -116.23% | YoY: -561.32%
EPS
Decreasing
-0.30
QoQ: -100.00% | YoY: -474.71%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q3 2025 4.19 -0.30 -20.2% View
Q2 2025 4.53 -0.15 -9.9% View
Q1 2025 4.20 -0.21 -13.0% View
Q4 2024 4.72 -0.23 +9.1% View
Q3 2024 5.24 -0.05 +3.9% View